ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$3.08 USD
+0.34 (12.41%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.08 USD
+0.34 (12.41%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
Molina (MOH) to Post Q4 Earnings: What You Should Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.
Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
by Zacks Equity Research
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
by Zacks Equity Research
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for ADC Therapeutics SA (ADCT) points to a 174.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?
by Zacks Equity Research
ADC Therapeutics SA (ADCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Land on 4 Winning Stocks Using the Overlooked Rising P/E Trick
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap four stocks, namely Eastside Distilling (EAST), AMC Entertainment (AMC), CuriosityStream (CURI) and ADC Therapeutics (ADCT).
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)
by Zacks Equity Research
The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
by Zacks Equity Research
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.
Earnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
ADC Therapeutics SA (ADCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growth in premiums.
Teladoc Health (TDOC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Teladoc Health's (TDOC) second-quarter results are likely to reflect growth in Subscription Access Fees.
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?